Gene Company Ltd
BEIJING YONGTAI XINGCHENG TRADING Co. Ltd
Exothera
Exothera is a Belgium-based CDMO delivering customized process development and GMP manufacturing services for gene therapy and viral vector-based vaccines. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide bespoke process optimization and GMP clinical and commercial production of viral vectors. Visit Exothera website >
Beijing Biolink Biotechnology Co. Ltd.
Shanghai Biotend Biological Technology Co. Ltd.
Shanghai Titan Scientific Co.,Ltd.
Sartorius
Sartorius Stedim Biotech is a supplier of equipment and services for development, quality assurance and production processes in the biopharmaceutical industry. Visit Sartorius website > Collaboration Article: Suspension-based production of lentiviral vectors for CAR T cell therapies
UNIMED Healthcare Inc
Aldevron
“Many of the plasmids made at Aldevron are used for lentivirus or AAV production. We have a lot of experience with different transfection agents. The scientists at Polyplus are world-class and have done a great job in developing enabling technologies like PEIpro-GMP.” – Michael Chambers, CEO at Aldevron
Beijing Oriental Innovation Biotechnology Co.,Ltd
Bizcom Japan., Ltd.
GenLab Biotech Company
MediTop Corporation Ltd
Alpha Labs Limited
GenoSci Technology Co Ltd
Ward Medic Ltd.
Hangzhou Haoke Biotechnology Co.,Ltd
Nanjing Fcmacs Biotechnology Co., Ltd.
Shanghai Universal Biotech Co., Ltd.
Sichuan Wisegene Biotechnologies Ltd
Wuhan Yangene Biological Technology Co.,LTD
Allergan
Allergan (Abbvie) is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Visit Allergan website > Collaboration Optimization of AAV process development: transfection matters Summary With the increased number of therapeutic rAAV candidates reaching the clinical trial pipeline, there is demand for innovative technologies...
Catalent
Check out this webinar hosted by BioInsight and featured by experts in transfection working at Polyplus-transfection, Audentes Therapeutic, Pall Life Sciences & Paragon Bioservices (Catalent). This webinar on “Optimizing process development to simplify manufacturing scale up of therapeutic viral vectors” is followed by a Question & Answer Session.
Cellvec
Niuqi Health
Chinese distributor specialized in lab services.
Corning
Since the introduction of our first products almost 100 years ago, laboratory professionals have come to rely on the Corning brand for quality products with features that make it easier to get work done. Whether cell culture, scale-up/bioprocess, or drug discovery, the Corning brand still delivers innovative vessels, advanced surfaces and quality media that help you get it right from...
FinVector
Généthon
Articles written by Polyplus-transfection featuring Généthon: Généthon and Polyplus-transfection team up to contribute to researching gene therapies for DMD Généthon and Polyplus-transfection team up to contribute to researching gene therapies for Duchenne Muscular Dystrophy (Article in Pharmaceutical Manufacturing). Read more… PEI-mediated virus production Advanced therapy medicinal products (ATMPs) including gene- and cell therapy-based medicines are experiencing resurgence due to the...
Molmed
ASGCT annual meeting, Washington DC, April 29th- May 2nd, 2019 TALK: Wednesday, May 1st at 4:30 pm Margherita Neri, PhD from Molmed gave a talk called “Lentiviral/Retroviral Vector Large Scale Manufacturing“, where she will present the results obtained with our PEIpro® and PEIpro®-HQ products. CTMGT Congress, Amsterdam (Netherlands), December 3 – 6th, 2019 Talk Wednesday, 4 December 2019, 15:30. Margherita Neri, PhD from Molmed Upstream Process Development...
Pieris
PEGS Europe meeting, Lisbon (Portugal), November 18-22th, 2019 Talk by Thibaut Angevin, PhD, Pieris Pharmaceuticals GmbH Nov. 21 – 12:15 : “Establishment of a CHO Transient Expression Platform for Bispecific Fusion Protein Developability Assessment”